ରୋଫ୍ଲୁମିଲାଷ୍ଟ

ରୋଫ୍ଲୁମିଲାଷ୍ଟ
	drugb
Clinical data
Trade names	Daxas, Daliresp, others
AHFS/Drugs.com	monograph
MedlinePlus	a611034
data	EU EMA: yes; US DailyMed: Roflumilast;
Pregnancy; category	AU: B3 ; US: N (Not classified yet) ; ;
Routes of; administration	By mouth
Legal status
Legal status	AU: S4 (Prescription only) ; CA: ℞-only ; UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ;
Pharmacokinetic data
Bioavailability	79%
Protein binding	99%
Metabolism	Liver via CYP1A2 & CYP3A4
Elimination half-life	17 hours (30 hours [active metabolite])
Excretion	Urine (70%)
Identifiers
	IUPAC name 3-(Cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide;
ECHA InfoCard	100.210.960
Chemical and physical data
Formula	C17H14Cl2F2N2O3
Molar mass	୪୦୩.୨୧ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F;
	InChI InChI=1S/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24) ; Key:MNDBXUUTURYVHR-UHFFFAOYSA-N ;
(verify)

ରୋଫ୍ଲୁମିଲାଷ୍ଟ, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଏକ ବିକ୍ରୟ ନାମ ଡାକ୍ସାସ, ଏକ ଔଷଧ ଯାହା ଏକ କ୍ରୋନିକ୍ ଅବସ୍ଟ୍ର‌କ୍ଟିଭ୍ ଫୁସଫୁସ ରୋଗର (COPD) ଦୀର୍ଘକାଳୀନ ପରିଚାଳନା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୬] ଏହା ଗୁରୁତର ରୋଗରେ ବ୍ୟବହୃତ ହୁଏ ^[୬] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୬]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ତରଳ ତରଳ ଝାଡ଼ା, ଅଇ, ମୁଣ୍ଡବିନ୍ଧା, ପିଠି ଯନ୍ତ୍ରଣା, ଶୋଇବାରେ ଅସୁବିଧା ଏବଂ ମୁଣ୍ଡ ବୁଲେଇବା ହୋଇପାରେ ।^[୭] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଆତ୍ମହତ୍ୟା ପ୍ରବଣ ଅନ୍ତର୍ଭୁକ୍ତ ହୋଇପାରେ ।^[୭] ଏହା ଏନଜାଇମ୍ ଫସଫୋଡାଇଇଷ୍ଟେରେଜ୍-୪ର (PDE-4) ଚୟନ‌କାରୀ ବାଧା ପ୍ରଦାନ‌କାରୀ ଏବଂ ଫୁସଫୁସ ପ୍ରଦାହକୁ ହ୍ରାସ କରି କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ ।^[୬]^[୧]

‌୨୦୧୦ ମସିହାରେ ୟୁରୋପରେ ଏବଂ ୨୦୧୧ରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ରୋଫ୍ଲୁମିଲାଷ୍ଟ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୧] ^[୮] ^[୭] ଯୁକ୍ତରାଜ୍ୟରେ ୨୦୨୧ ସୁଦ୍ଧା ପ୍ରତି ମାସରେ ୩୮ ପାଉଣ୍ଡ ଖର୍ଚ୍ଚ ହୋଇଥାଏ ।^[୯] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୪୩୦ ଡଲାର ଅଟେ ।^[୧୦]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ "Daxas EPAR". European Medicines Agency. Archived from the original on 12 August 2020. Retrieved 28 September 2020.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ "Daxas 250 micrograms tablets - Summary of Product Characteristics (SmPC)". (emc). 11 June 2020. Archived from the original on 19 September 2020. Retrieved 28 September 2020.
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ ^୩.୫ "Daliresp- roflumilast tablet". DailyMed. 12 March 2020. Archived from the original on 25 March 2021. Retrieved 28 September 2020.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ "Daliresp : EPAR - Product Information" (PDF). European Medicines Agency. Takeda GmbH. 26 September 2013. Archived (PDF) from the original on 26 June 2016. Retrieved 18 November 2013.
↑ ^୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ ^୫.୪ "roflumilast (Rx) - Daliresp". Medscape Reference. WebMD. Archived from the original on 12 September 2017. Retrieved 18 November 2013.
↑ ^୬.୦ ^୬.୧ ^୬.୨ ^୬.୩ "Roflumilast Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 25 February 2021. Retrieved 18 October 2021.
↑ ^୭.୦ ^୭.୧ ^୭.୨ "DailyMed - DALIRESP- roflumilast tablet". dailymed.nlm.nih.gov. Archived from the original on 25 March 2021. Retrieved 18 October 2021.
↑ ""Nycomed's Anti-Inflammatory Gains Approval in EU for COPD"". Archived from the original on 2017-08-24. Retrieved 2021-07-21.
↑ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 286. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
↑ "Daliresp Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 11 April 2021. Retrieved 18 October 2021.

[EPAR2021-1] ୧.୦ ^୧.୧ ^୧.୨ "Daxas EPAR". European Medicines Agency. Archived from the original on 12 August 2020. Retrieved 28 September 2020.

[Daxas_SmPC-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ "Daxas 250 micrograms tablets - Summary of Product Characteristics (SmPC)". (emc). 11 June 2020. Archived from the original on 19 September 2020. Retrieved 28 September 2020.

[Daliresp_FDA_label-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ ^୩.୫ "Daliresp- roflumilast tablet". DailyMed. 12 March 2020. Archived from the original on 25 March 2021. Retrieved 28 September 2020.

[EMA-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ "Daliresp : EPAR - Product Information" (PDF). European Medicines Agency. Takeda GmbH. 26 September 2013. Archived (PDF) from the original on 26 June 2016. Retrieved 18 November 2013.

[MSR-5] ୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ ^୫.୪ "roflumilast (Rx) - Daliresp". Medscape Reference. WebMD. Archived from the original on 12 September 2017. Retrieved 18 November 2013.

[AHFS2021-6] ୬.୦ ^୬.୧ ^୬.୨ ^୬.୩ "Roflumilast Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 25 February 2021. Retrieved 18 October 2021.

[PI2021-7] ୭.୦ ^୭.୧ ^୭.୨ "DailyMed - DALIRESP- roflumilast tablet". dailymed.nlm.nih.gov. Archived from the original on 25 March 2021. Retrieved 18 October 2021.

[8] ""Nycomed's Anti-Inflammatory Gains Approval in EU for COPD"". Archived from the original on 2017-08-24. Retrieved 2021-07-21.

[BNF80-9] BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 286. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[10] "Daliresp Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 11 April 2021. Retrieved 18 October 2021.

[୨]

[୩]

[୧]

[୪]

[୫]

[୬]

[୭]

[୮]

[୯]

[୧୦]